MARKET

JAZZ

JAZZ

Jazz Phrmt
NASDAQ

Real-time Quotes | Nasdaq Last Sale

120.58
+1.84
+1.55%
Opening 11:29 06/04 EDT
OPEN
118.74
PREV CLOSE
118.74
HIGH
120.99
LOW
117.88
VOLUME
122.17K
TURNOVER
--
52 WEEK HIGH
154.24
52 WEEK LOW
86.88
MARKET CAP
6.67B
P/E (TTM)
25.05
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average JAZZ stock price target is 153.76 with a high estimate of 193.00 and a low estimate of 109.00.

EPS

JAZZ News

More
Jazz Pharmaceuticals: Pandemic Leaves The Leading Drug In A Catch 22
Seeking Alpha - Article · 2d ago
Insider Weekends: Activist Investors Add To Their Avid Technology Stake
Seeking Alpha - Article · 3d ago
10 Biggest Price Target Changes For Monday
Wedbush raised the price target for Chipotle Mexican Grill, Inc. (NYSE: CMG) from $870 to $1200. Chipotle shares closed at $1,003.91 on Friday.
Benzinga · 3d ago
SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $169
SVB Leerink maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $160 to $169.
Benzinga · 3d ago
Top Insider Buys Highlight for the Week of May 29
GuruFocus.com · 4d ago
Notable Insider Buys: Avis, Dynavax And Formula One
Insider buying can be an encouraging signal for potential investors.Beneficial owner Berkshire Hathaway made a huge purchase last week.A director took advantage of a coronavirus vaccine contender's secondary offering.
Benzinga · 4d ago
Informative Insider Purchasing Activity - Weekly Update (05/22/20-05/29/20)
Seeking Alpha - Article · 5d ago
2 Top Healthcare Stocks to Buy Right Now
MotleyFool.com · 05/28 09:54

Industry

Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.05%

Hot Stocks

Symbol
Price
%Change

About JAZZ

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
More

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.